ADDFBeyond's analysis on ADDF2026-07-14 — FDA’s approval of a weekly subcutaneous starting dose for Leqembi enables at-home initiation of Alzheimer’s therapy, moving the drug toward combination‑therapy regimensRecent news mentioning ADDF2026-08-20 — FDA Clearance of C2N Diagnostics' PrecivityAD2 Blood Test Advances Precision Medicine for Alzheimer's, Building on Groundwork Laid by Early ADDF Investment2026-07-13 — ADDF Statement: FDA Approval of Subcutaneous Starting Dose for Leqembi Advances Alzheimer's Care Toward Combination Therapy FutureBrowse the full archive →